BNP Paribas Financial Markets Has $59.58 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

BNP Paribas Financial Markets boosted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 40.4% in the first quarter, HoldingsChannel reports. The firm owned 431,982 shares of the company’s stock after buying an additional 124,352 shares during the period. BNP Paribas Financial Markets’ holdings in Neurocrine Biosciences were worth $59,579,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Retirement Systems of Alabama grew its holdings in Neurocrine Biosciences by 1.5% in the first quarter. Retirement Systems of Alabama now owns 124,955 shares of the company’s stock worth $17,234,000 after purchasing an additional 1,899 shares during the period. Norden Group LLC acquired a new position in shares of Neurocrine Biosciences during the first quarter valued at about $393,000. Van ECK Associates Corp grew its holdings in shares of Neurocrine Biosciences by 1,325.5% during the first quarter. Van ECK Associates Corp now owns 92,243 shares of the company’s stock valued at $12,722,000 after buying an additional 85,772 shares during the last quarter. Caprock Group LLC acquired a new position in shares of Neurocrine Biosciences during the first quarter valued at about $215,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Neurocrine Biosciences by 23.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 506,666 shares of the company’s stock valued at $69,879,000 after buying an additional 96,563 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Oppenheimer lifted their price objective on shares of Neurocrine Biosciences from $200.00 to $216.00 and gave the company an “outperform” rating in a report on Thursday, May 2nd. Wells Fargo & Company upgraded shares of Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $140.00 to $170.00 in a report on Wednesday, April 24th. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, April 10th. JPMorgan Chase & Co. lifted their price objective on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the company an “overweight” rating in a report on Wednesday, March 20th. Finally, UBS Group lifted their price objective on shares of Neurocrine Biosciences from $174.00 to $193.00 and gave the company a “buy” rating in a report on Tuesday, May 28th. Six equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $152.00.

Insider Transactions at Neurocrine Biosciences

In other news, Director Shalini Sharp sold 1,106 shares of Neurocrine Biosciences stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $141.90, for a total value of $156,941.40. Following the completion of the transaction, the director now owns 994 shares in the company, valued at $141,048.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Ingrid Delaet sold 273 shares of the business’s stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $140.55, for a total transaction of $38,370.15. Following the completion of the transaction, the insider now owns 7,507 shares of the company’s stock, valued at $1,055,108.85. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Shalini Sharp sold 1,106 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $141.90, for a total transaction of $156,941.40. Following the transaction, the director now directly owns 994 shares of the company’s stock, valued at approximately $141,048.60. The disclosure for this sale can be found here. Insiders sold 98,697 shares of company stock worth $13,377,515 over the last quarter. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Stock Performance

NBIX stock traded up $0.85 during mid-day trading on Friday, hitting $139.08. The company had a trading volume of 445,245 shares, compared to its average volume of 730,587. The firm has a market cap of $14.00 billion, a PE ratio of 38.31 and a beta of 0.37. Neurocrine Biosciences, Inc. has a 12 month low of $93.28 and a 12 month high of $148.37. The stock’s fifty day moving average price is $137.48 and its two-hundred day moving average price is $136.22.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $1.04 by ($0.62). The business had revenue of $515.30 million during the quarter, compared to analysts’ expectations of $512.21 million. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. Equities analysts anticipate that Neurocrine Biosciences, Inc. will post 4.22 earnings per share for the current year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.